Structures by: Insuasty B.
Total: 79
1-Benzyl-3-hydroxy-3-[2-(4-methoxyphenyl)-2-oxoethyl]indolin-2-one
C24H21NO4
Acta Crystallographica Section C (2020) 76, 5 433-445
a=18.7572(14)Å b=13.2095(10)Å c=16.750(2)Å
α=90° β=105.374(5)° γ=90°
1-Benzyl-3-{2-[4-(dimethylamino)phenyl]-2-oxoethyl}-3-hydroxyindolin-2-one
C25H24N2O3
Acta Crystallographica Section C (2020) 76, 5 433-445
a=9.1028(8)Å b=10.6434(9)Å c=11.2539(10)Å
α=88.988(3)° β=68.422(3)° γ=81.352(3)°
(<i>E</i>)-1-Benzyl-3-[2-(4-fluorophenyl)-2-oxoethylidene]indolin-2-one
C23H16FNO2
Acta Crystallographica Section C (2020) 76, 5 433-445
a=7.6021(6)Å b=20.4880(13)Å c=10.9319(7)Å
α=90° β=96.986(3)° γ=90°
1-Benzyl-3-hydroxy-3-[2-oxo-2-(pyridin-4-yl)ethyl]indolin-2-one
C22H18N2O3
Acta Crystallographica Section C (2020) 76, 5 433-445
a=7.8838(5)Å b=10.1766(8)Å c=11.8719(9)Å
α=87.554(3)° β=75.996(2)° γ=69.428(2)°
(<i>E</i>)-1-Benzyl-3-[2-oxo-2-(pyridin-4-yl)ethylidene]indolin-2-one
C22H16N2O2
Acta Crystallographica Section C (2020) 76, 5 433-445
a=7.3457(6)Å b=18.0675(16)Å c=13.1813(13)Å
α=90° β=105.994(3)° γ=90°
(<i>E</i>)-1-Benzyl-3-[2-(4-methoxyphenyl)-2-oxoethylidene]indolin-2-one
C24H19NO3
Acta Crystallographica Section C (2020) 76, 5 433-445
a=4.9743(2)Å b=29.1957(13)Å c=12.4406(6)Å
α=90° β=100.914(2)° γ=90°
(<i>E</i>)-1-Benzyl-3-[2-oxo-2-(thiophen-2-yl)ethylidene]indolin-2-one
C21H15NO2S
Acta Crystallographica Section C (2020) 76, 5 433-445
a=17.5058(14)Å b=8.8163(6)Å c=21.2092(16)Å
α=90° β=90° γ=90°
3-[2-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-2-oxoethyl]-1-benzyl-3-hydroxyindolin-2-one
C24H19NO5
Acta Crystallographica Section C (2020) 76, 5 433-445
a=11.8136(7)Å b=12.4987(10)Å c=13.5976(11)Å
α=93.084(3)° β=101.883(2)° γ=95.055(2)°
(<i>E</i>)-1-Benzyl-5-chloro-3-[2-(4-chlorophenyl)-2-oxoethylidene]indolin-2-one
C23H15Cl2NO2
Acta Crystallographica Section C (2020) 76, 5 433-445
a=8.2010(6)Å b=9.7629(7)Å c=12.1740(9)Å
α=76.755(3)° β=87.675(3)° γ=76.211(3)°
(<i>E</i>)-3-{5-[Benzyl(methyl)amino]-3-methyl-1-phenyl-1<i>H</i>-pyrazol-4-yl}-1-(4-bromophenyl)prop-2-en-1-one
C27H24BrN3O
Acta crystallographica. Section C, Structural chemistry (2017) 73, Pt 10 784-790
a=31.172(16)Å b=10.039(6)Å c=17.861(10)Å
α=90° β=123.334(14)° γ=90°
5-[Benzyl(methyl)amino]-3-methyl-1-phenyl-1<i>H</i>-pyrazole-4-carbaldehyde
C19H19N3O
Acta crystallographica. Section C, Structural chemistry (2017) 73, Pt 10 784-790
a=7.811(4)Å b=17.951(9)Å c=11.405(6)Å
α=90° β=92.36(2)° γ=90°
(3<i>RS</i>)-5'-[Benzyl(methyl)amino]-3'-methyl-1',5-diphenyl-3,4-dihydro-1'<i>H</i>,2<i>H</i>-[3,4'-bipyrazole]-2-carbaldehyde
C28H27N5O
Acta crystallographica. Section C, Structural chemistry (2017) 73, Pt 10 784-790
a=11.321(5)Å b=21.572(13)Å c=9.550(5)Å
α=90° β=97.711(18)° γ=90°
(3<i>RS</i>)-2-acetyl-5'-[Benzyl(methyl)amino]- 5-(4-methoxyphenyl)-3'-methyl-1'-phenyl-3,4-dihydro-1'<i>H</i>,2<i>H</i>-[3,4'-bipyrazole] ethanol 0.945-solvate
C30H31N5O2,0.945C2H6O
Acta crystallographica. Section C, Structural chemistry (2017) 73, Pt 10 784-790
a=9.363(6)Å b=28.238(18)Å c=10.775(7)Å
α=90° β=97.04(2)° γ=90°
2-Ethylsulfanyl-7-(furan-2-yl)-4-(thiophen-2-yl)pyrazolo[1,5-<i>a</i>][1,3,5]triazine
C15H12N4OS2
Acta crystallographica. Section C, Structural chemistry (2014) 70, Pt 9 908-911
a=7.4999(4)Å b=8.8965(5)Å c=11.2806(9)Å
α=83.338(6)° β=73.354(5)° γ=86.406(6)°
1-(4-bromophenyl)-3-[2-(2-hydroxyethyl)amino-5-nitroanilino]-1-propanone
C17H18BrN3O4,C3H7NO
Acta Crystallographica Section E (2003) 59, 3 o296-o298
a=10.5267(2)Å b=10.7688(3)Å c=10.9397(3)Å
α=77.646(2)° β=72.743(2)° γ=62.7565(12)°
5-(Benzo[1,3]dioxol-5-yl)-7-(4-chloro-phenyl)-3-methyl-1-phenyl-1,6,7,8- tetrahydropyrazolo[3,4-b][1,4]diazepine
C26H21ClN4O2
Acta Crystallographica Section E (2003) 59, 1 o18-o20
a=11.3422(2)Å b=15.6889(3)Å c=24.1716(5)Å
α=90.00° β=92.4370(10)° γ=90.00°
5-(1,3-benzodioxol-5-yl)-3-methyl-1,7-diphenyl-1,6,7,8-tetrahydropyrazolo [3,4-b][1,4]diazepine
C26H22N4O2
Acta Crystallographica Section E (2003) 59, 5 o614-o615
a=10.2608(8)Å b=10.9910(6)Å c=11.2485(8)Å
α=63.656(4)° β=63.573(3)° γ=77.080(5)°
1-chloroacetyl-2,4-diphenyl-2,3-dihydro-1H-1,5-benzodiazepine
C23H19ClN2O
Acta Crystallographica Section E (2003) 59, 5 o603-o605
a=31.7081(8)Å b=7.8174(2)Å c=15.4208(5)Å
α=90.00° β=104.3440(10)° γ=90.00°
6-(4-fluorophenyl)-5,6-dihydrobenzimidazo[1,2-c]quinazoline
C20H14FN3
Acta Crystallographica, Section E: Structure Reports Online (2003) 59, 11 o1801-o1803
a=22.3211(8)Å b=22.3211(8)Å c=17.2220(9)Å
α=90.00° β=90.00° γ=120.00°
4-(4-bromophenyl)-3,7,7-trimethyl-4,7,8,9-tetrahydro-2H-pyrazolo[3,4-b] quinolin-5(6H)-one
C19H20BrN3O
Acta Crystallographica Section E (2001) 57, 2 o151-o153
a=8.6673(2)Å b=14.6092(3)Å c=14.4783(5)Å
α=90.00° β=107.2870(10)° γ=90.00°
3,7,7-Trimethyl-4-(β-naphthyl)-4,7,8,9-tetrahydro-2H-pyrazolo[3,4-b]- quinolin-5(6H)-one
C23H23N3O
Acta Crystallographica Section E (2001) 57, 2 o160-o162
a=9.1222(18)Å b=15.281(3)Å c=14.346(3)Å
α=90.00° β=106.13(3)° γ=90.00°
5-(1,3-Benzothiazol-2-yliminomethyl)-2,2-dimethyl-1,3-dioxane-4,6-dione
C14H12N2O4S
Acta Crystallographica Section E (2001) 57, 2 o180-o181
a=6.3459(13)Å b=19.235(4)Å c=11.144(2)Å
α=90.00° β=103.07(3)° γ=90.00°
6-(2-Hydroxybenzoyl)-2-(4-nitrophenyl)pyrazolo[1,5-a]pyrimidine
C19H12N4O4
Acta Crystallographica Section E (2001) 57, 2 o182-o184
a=5.5421(2)Å b=11.5858(5)Å c=23.8057(13)Å
α=90.00° β=90.00° γ=90.00°
5,5-Dimethyl-3-[(5-phenyl-1H-pyrazol-3-yl)amino]cyclohex-2-en-1-one
C17H19N3O
Acta Crystallographica Section E (2001) 57, 2 o185-o186
a=19.0427(2)Å b=9.6024(4)Å c=16.6135(7)Å
α=90.00° β=90.00° γ=90.00°
6-(2-hydroxybenzoyl)-2-phenylpyrazolo[1,5-a]pyrimidine
C19H13N3O2
Acta Crystallographica Section E (2001) 57, 2 o187-o188
a=5.6606(2)Å b=11.7048(5)Å c=21.6815(10)Å
α=90.00° β=94.7970(15)° γ=90.00°
3,7,7-Trimethyl-4-(4-methoxyphenyl)-4,7,8,9-tetrahydro-2H-pyrazolo[3,4-b]- quinolin-5(6H)-one (4).
C20H23N3O2
Acta Crystallographica Section E (2001) 57, 2 o154-o156
a=8.5820(3)Å b=14.7031(5)Å c=14.5369(8)Å
α=90.00° β=106.0610(15)° γ=90.00°
3,7,7-Trimethyl-4-phenyl-4,7,8,9-tetrahydro-2H-pyrazolo[3,4-b]quinolin-5- (6H)-one
C19H21N3O
Acta Crystallographica Section E (2001) 57, 2 o157-o159
a=10.0870(5)Å b=14.1978(5)Å c=11.1928(8)Å
α=90.00° β=96.0340(14)° γ=90.00°
6-(1H-1,2,3-Benzotriazol-1-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinoline
C17H16N4
Acta Crystallographica Section E (2001) 57, 2 o178-o179
a=10.7112(3)Å b=10.8297(3)Å c=23.6321(5)Å
α=90.00° β=90.00° γ=90.00°
5-[(Dimethylamino)methyleneamino]-3-methyl-1-phenylpyrazole
C13H16N4
Acta Crystallographica Section C (1999) 55, 12 2096-2098
a=9.1149(6)Å b=7.5153(4)Å c=18.1463(8)Å
α=90.00° β=92.030(10)° γ=90.00°
5-Cyano-4-(4-methoxyphenyl)-3,6-diphenyl-4,7-dihydro-2H-pyrazolo- [3,4-b]pyridine
C26H20N4O
Acta Crystallographica Section C (1999) 55, 12 IUC9900168
a=15.6264(3)Å b=12.4397(2)Å c=21.1296(4)Å
α=90.00° β=91.4371(9)° γ=90.00°
3,4-Bis(4-chlorophenyl)-5-cyano-6-phenyl-1H-pyrazolo-[3,4-b]pyridine
C25H14Cl2N4
Acta Crystallographica Section C (1999) 55, 12 IUC9900168
a=6.6222(5)Å b=11.0791(10)Å c=28.264(2)Å
α=90.00° β=96.248(5)° γ=90.00°
4-(4-chlorophenyl)-5-cyano-3-(4-methylphenyl)-6-diphenyl-4,7-dihydro-2H-pyrazolo [3,4-b]pyridine:dimethylformamide (2/1)
2C26H19ClN4,C3H7NO
Acta Crystallographica Section C (1999) 55, 12 IUC9900168
a=12.4124(5)Å b=13.8275(4)Å c=14.3744(6)Å
α=91.747(2)° β=106.6376(17)° γ=99.610(2)°
(Z)-2-(Dimethylamino)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazolidin-4-one
C15H18N2O4S
Acta Crystallographica Section E (2007) 63, 3 o1123-o1125
a=29.259(6)Å b=7.6410(15)Å c=14.336(3)Å
α=90.00° β=110.59(3)° γ=90.00°
2-{2-[2-(4-Methoxybenzoyl)ethylamino]-4-nitroanilino}ethyl acetate
C20H23N3O6
Acta Crystallographica Section C (2009) 65, 9 o483-o486
a=34.3729(17)Å b=8.7718(5)Å c=13.6662(9)Å
α=90.00° β=111.847(2)° γ=90.00°
(8<i>RS</i>)-4-Amino-6-(4-chlorophenyl)-8-(2,4-dichlorothiazol-5-yl)-8,9-dihydro-7<i>H</i>-pyrimido[4,5-<i>b</i>][1,4]diazepine <i>N</i>,<i>N</i>-dimethylformamide monosolvate
C16H11Cl3N6S,C3H7NO
Acta Crystallographica Section C (2014) 70, 6 536-540
a=9.2934(6)Å b=10.9680(10)Å c=11.7071(10)Å
α=69.610(8)° β=87.450(6)° γ=74.688(6)°
(<i>E</i>)-3-{4-[(7-Chloroquinolin-4-yl)oxy]-3-methoxyphenyl}-1-(4-methylphenyl)prop-2-en-1-one
C26H20ClNO3
Acta Crystallographica Section C (2014) 70, 7 677-680
a=7.9521(9)Å b=32.170(3)Å c=8.5382(10)Å
α=90.00° β=108.240(16)° γ=90.00°
6-amino-3-methyl-5-nitroso-2-(pyrrolidin-1- yl)pyrimidin-4(3<i>H</i>)-one monohydrate
C9H13N5O2,H2O
Acta Crystallographica Section C (2009) 65, 11 o549-o552
a=7.9734(18)Å b=8.452(2)Å c=8.9099(2)Å
α=75.158(9)° β=84.727(7)° γ=64.436(16)°
4,6-Diamino-2-morpholino-5-nitrosopyrimidine
C8H12N6O2
Acta Crystallographica Section C (2009) 65, 12 o598-o600
a=6.3340(7)Å b=19.247(3)Å c=8.4472(12)Å
α=90.00° β=110.562(13)° γ=90.00°
6-amino-2-dimethylamino-3-methyl-5-nitrosopyrimidin-4(3<i>H</i>)-one monohydrate
C7H11N5O2,H2O
Acta Crystallographica Section C (2009) 65, 11 o549-o552
a=11.8125(6)Å b=7.1372(7)Å c=11.8588(19)Å
α=90.00° β=107.910(4)° γ=90.00°
3-Benzyl-2-(4-fluorophenyl)-1,3-thiazolidin-4-one
C16H14FNOS
Acta Crystallographica Section C (2011) 67, 1 o10-o12
a=9.6931(9)Å b=16.8888(16)Å c=16.4202(18)Å
α=90.00° β=94.706(12)° γ=90.00°
2-Ethyl-1-[5-(4-methylphenyl)pyrazol-3-yl]-3-(thiophen-2-carbonyl)isothiourea
C18H18N4OS2
Acta Crystallographica Section C (2014) 70, 11 1064-1068
a=7.998(2)Å b=11.085(3)Å c=11.696(2)Å
α=61.92(2)° β=84.921(18)° γ=79.928(19)°
(<i>Z</i>)-5-[(5-Methyl-1<i>H</i>-imidazol-4-yl)methylidene]-2-sulfanylidene- 1,3-thiazolidin-4-one monohydrate
C8H7N3OS2,H2O
Acta Crystallographica Section C (2012) 68, 11 o468-o471
a=7.4110(6)Å b=16.2739(18)Å c=17.201(2)Å
α=90.00° β=90.00° γ=90.00°
2-(4-Bromophenyl)-1,2-dihydropyrimido[1,2-a]benzimidazol-4(3H)-one
C16H12BrN3O
Acta Crystallographica Section C (2002) 58, 2 o125-o128
a=6.8807(2)Å b=16.2254(6)Å c=13.3379(5)Å
α=90° β=111.280(2)° γ=90°
3-methyl-1,5-diphenyl-1,6,7,8-tetrahydropyrazolo[3,4-b][1,4]diazepine
C19H18N4
Acta Crystallographica Section C (2002) 58, 2 o103-o105
a=30.5212(7)Å b=30.5212(7)Å c=8.8689(2)Å
α=90.00° β=90.00° γ=120.00°
5-(4-Chlorophenyl)-3-methyl-1-phenyl-1,6,7,8- tetrahydropyrazolo[3,4-b][1,4]diazepine
C19H17ClN4
Acta Crystallographica Section C (2002) 58, 2 o103-o105
a=9.0066(18)Å b=17.969(4)Å c=18.007(4)Å
α=115.73(3)° β=101.02(3)° γ=98.83(3)°
4-(4-Methylphenyl)-3,4-dihydropyrimido[1,2-a]benzimidazol-2(1H)-one
C17H15N3O
Acta Crystallographica Section C (2002) 58, 2 o125-o128
a=8.1360(3)Å b=9.8647(4)Å c=10.0975(5)Å
α=114.8796(13)° β=94.9156(15)° γ=100.966(3)°
3-methyl-1,4-diphenyl-1H-pyrazolo-(3,4-b)pyridine
C19H15N3
Acta Crystallographica Section C (2002) 58, 5 o298-o300
a=8.1392(4)Å b=8.4351(4)Å c=11.3852(6)Å
α=77.951(3)° β=81.192(2)° γ=70.681(2)°
3-hydroxy-3-[(4-methylbenzoyl)methyl]indolin-2-one
C17H15NO3
Acta Crystallographica Section C (2010) 66, 2 o79-o86
a=6.873(2)Å b=7.6700(17)Å c=13.394(5)Å
α=99.48(2)° β=101.68(3)° γ=96.33(2)°
3-benzoylmethyl-3-hydroxyindolin-2-one
C16H13NO3
Acta Crystallographica Section C (2010) 66, 2 o79-o86
a=13.876(3)Å b=5.7725(8)Å c=16.280(3)Å
α=90.00° β=107.799(16)° γ=90.00°
3-hydroxy-3-[(4-fluorobenzoyl)methyl]indolin-2-one
C16H12FNO3
Acta Crystallographica Section C (2010) 66, 2 o79-o86
a=6.8858(7)Å b=7.7074(8)Å c=12.7010(9)Å
α=98.229(7)° β=103.667(7)° γ=96.034(9)°
3-hydroxy-3-[(4-chlorobenzoyl)methyl]indolin-2-one
C16H12ClNO3
Acta Crystallographica Section C (2010) 66, 2 o79-o86
a=6.987(2)Å b=7.689(4)Å c=12.907(4)Å
α=99.30(3)° β=101.82(4)° γ=96.33(3)°
3-[(4-bromobenzoyl)methyl]-3-hydroxyindolin-2-one
C16H12BrNO3
Acta Crystallographica Section C (2010) 66, 2 o79-o86
a=7.016(3)Å b=7.7349(12)Å c=13.052(6)Å
α=99.69(3)° β=101.51(4)° γ=96.70(3)°
3-hydroxy-3-[(4-nitrobenzoyl)methyl]indolin-2-one
C16H12N2O5
Acta Crystallographica Section C (2010) 66, 2 o79-o86
a=7.0260(10)Å b=7.598(3)Å c=13.365(4)Å
α=97.54(3)° β=102.67(2)° γ=96.46(2)°
3-hydroxy-3-(2-thienylcarbonylmethyl)indolin-2-one
C14H11NO3S
Acta Crystallographica Section C (2010) 66, 2 o79-o86
a=6.5958(7)Å b=7.9577(14)Å c=12.045(3)Å
α=78.51(2)° β=76.555(13)° γ=84.559(15)°
Rac-3-(5-Amino-3-methyl-1-phenyl-1H-pyrazol-4-yl)-2-phenyl-thiazolidin-4-one
C19H18N4OS
Acta Crystallographica Section C (2004) 60, 7 o486-o488
a=10.7937(4)Å b=11.3989(2)Å c=14.2448(5)Å
α=79.993(2)° β=83.3490(14)° γ=89.852(2)°
(<i>Z</i>)-5-[4-(Dimethylamino)benzylidene]-2-(piperidin-1-yl)- 1,3-thiazolidin-4(5<i>H</i>)-one
C17H21N3OS
Acta Crystallographica Section C (2013) 69, 1 74-76
a=12.7125(14)Å b=7.8246(4)Å c=16.579(2)Å
α=90.00° β=106.904(9)° γ=90.00°
5-(3-(4-methylphenyl)-2-propenylidene]-2,2-dimethyl-[1,3] dioxane-4,6-dione
C16H16O4
Acta Crystallographica Section C (2002) 58, 1 o39-o41
a=11.2891(3)Å b=11.4128(4)Å c=13.4504(5)Å
α=91.217(2)° β=114.640(3)° γ=113.7590(15)°
5-(3-(4-chlorophenyl)-2-propenylidene]-2,2-dimethyl-[1,3] dioxane-4,6-dione
C15H13ClO4
Acta Crystallographica Section C (2002) 58, 1 o39-o41
a=7.2648(2)Å b=7.4705(3)Å c=13.5855(6)Å
α=90.1799(13)° β=99.8452(14)° γ=109.576(3)°
3-{[4-Amino-6-methoxy-2-(methylsulfanyl)pyrimidin-5-yl]amino}-1,2'- biindenylidene-1',3'-dione dimethyl sulfoxide solvate
C24H18N4O3S,C2H6OS
Acta Crystallographica Section C (2009) 65, 5 o229-o232
a=10.6056(5)Å b=10.9946(11)Å c=12.6770(11)Å
α=69.780(13)° β=76.523(5)° γ=64.484(7)°
Piperidinium 6-amino-3-methyl-5-nitroso-2,4-dioxo-1,2,3,tetrahydropyrimidin-1-ide 6-amino-3-methyl-5-nitrosopyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione
C5H12N,C5H5N4O3,C5H6N4O3
Acta Crystallographica Section C (2009) 65, 5 o257-o260
a=9.3287(19)Å b=13.1352(10)Å c=16.2814(19)Å
α=87.815(10)° β=74.095(10)° γ=89.987(16)°
(9<i>E</i>)-9-Benzylidene-2-methylsulfanyl-5-phenyl-6,7,8,9-tetrahydropyrimido[4,5-<i>b</i>]quinolin-4(3<i>H</i>)-one
C25H21N3OS
Acta Crystallographica Section C (2013) 69, 12 1524-1526
a=9.2168(16)Å b=9.7617(18)Å c=12.6839(17)Å
α=77.688(16)° β=75.951(11)° γ=68.117(13)°
(9E)-9-benzylidene-3-methyl-2-(methylthio)-5-phenyl- 5,6,7,8,9,10-hexahydropyrimido[4,5-<i>b</i>]quinolin- 4(3<i>H</i>)-one
C26H25N3OS
Acta Crystallographica Section C (2010) 66, 8 o389-o391
a=8.382(2)Å b=10.777(3)Å c=12.745(4)Å
α=73.18(3)° β=85.13(4)° γ=76.43(3)°
2-Hydroxyphenyl 2-methylpyrazolo[1,5-a]pyrimidin-6-yl ketone
C14H11N3O2
Acta Crystallographica Section C (2000) 56, 12 1455-1456
a=5.6004(2)Å b=11.8172(5)Å c=17.865(7)Å
α=90.00° β=98.71(16)° γ=90.00°
2,4-bis(2-hydroxybenzoyl)-2,3-dihydro-1H-pyrido[2,1-b][1,3]benzothiazole
C25H19NO4S
Acta Crystallographica Section C (2000) 56, 12 1460-1461
a=7.4978(15)Å b=11.265(2)Å c=12.322(3)Å
α=108.12(3)° β=99.38(3)° γ=94.75(3)°
2-Phenyl-5-p-tolyl-1,5,6,10b-tetrahydropyrazolo[1,5-c]quinazoline
C23H21N3
Acta Crystallographica Section C (2002) 58, 5 o305-o310
a=8.5292(12)Å b=10.7291(16)Å c=11.0469(16)Å
α=109.417(2)° β=91.555(3)° γ=110.945(3)°
5-(4-Bromophenyl)-2-phenyl-1,5,6,10b-tetrahydropyrazolo[1,5-c]quinazoline
C22H18BrN3
Acta Crystallographica Section C (2002) 58, 5 o305-o310
a=8.5110(2)Å b=10.7015(3)Å c=11.0357(3)Å
α=110.036(2)° β=92.1613(15)° γ=110.3276(10)°
2-(4-Chlorophenyl)-5-phenyl-1,5,6,10b-tetrahydropyrazolo[1,5-c]quinazoline
C22H18ClN3
Acta Crystallographica Section C (2002) 58, 5 o305-o310
a=21.2115(3)Å b=11.1385(2)Å c=17.5948(4)Å
α=90° β=122.4270(10)° γ=90°
5-(4-Bromophenyl)-2-(4-chlorophenyl)-1,5,6,10b-tetrahydropyrazolo[1,5-c] quinazoline
C22H17BrClN3
Acta Crystallographica Section C (2002) 58, 5 o305-o310
a=5.55600(10)Å b=12.2526(2)Å c=14.0827(3)Å
α=77.9230(9)° β=83.0060(8)° γ=87.8140(10)°
2-Aminobenzimidazolium O-ethyl malonate
C7H8N31,C5H7O41
Acta Crystallographica Section C (2003) 59, 12 o669-o671
a=12.0121(2)Å b=10.5379(2)Å c=20.8249(6)Å
α=90.00° β=94.7550(8)° γ=90.00°
1,5-Bis(4-chlorophenyl)-3-(2-chloroquinolin-3-yl)pentane-1,5-dione
C26H18Cl3NO2
Acta Crystallographica Section C (2006) 62, 1 o39-o41
a=11.2405(2)Å b=18.8738(3)Å c=21.0529(3)Å
α=90.00° β=90.00° γ=90.00°
5-Chloro-3-methyl-4-[3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-1-phenyl- 1H-pyrazole
C19H16ClN5O2
Acta Crystallographica Section C (2006) 62, 1 o30-o32
a=5.5055(2)Å b=11.8317(3)Å c=13.5668(4)Å
α=83.3210(17)° β=78.9560(17)° γ=86.3960(18)°
1-Benzyl-4-(4-nitrophenyl)-2,3-dihydro-1H-1,5-benzodiazepine
C22H19N3O2
Acta Crystallographica Section C (2005) 61, 6 o404-o407
a=7.3810(2)Å b=10.8016(3)Å c=22.1319(5)Å
α=90.00° β=90.00° γ=90.00°
Dispiro[indene-2,5'-indeno[2,1-a]fluorene-6',2''-indene]- 1,1'',3,3'',11',12'-hexaone
C36H16O6
Acta Crystallographica Section C (2008) 64, 3 o162-o165
a=8.2209(11)Å b=16.552(3)Å c=18.423(3)Å
α=90.00° β=97.775(19)° γ=90.00°
6-amino-3-methyl-2-(morpholin-4-yl)-5-nitrosopyrimidin-4(3H)-one
C9H13N5O3
Acta Crystallographica Section C (2008) 64, 4 o220-o225
a=8.9122(6)Å b=11.9051(7)Å c=10.4111(4)Å
α=90.00° β=105.649(3)° γ=90.00°
Morpholin-4-ium 4-amino-2-(morpholin-4-yl)-5-nitroso-6-oxo-1,6-dihydropyrimidin-1-ide
C4H10NO,C8H10N5O3
Acta Crystallographica Section C (2008) 64, 4 o220-o225
a=9.4410(11)Å b=16.347(4)Å c=18.799(5)Å
α=90.00° β=90.045(15)° γ=90.00°
6-amino-2-(morpholin-4-yl)-5-nitrosopyrimidin-4(3H)-one hemihydrate
C8H11N5O3,0.5(H2O)
Acta Crystallographica Section C (2008) 64, 4 o220-o225
a=16.421(2)Å b=7.3671(12)Å c=17.205(4)Å
α=90.00° β=104.794(12)° γ=90.00°
Hexamethylenediammonium bis(chloroacetate)
C6H18N22,2C2H2ClO2
Acta Crystallographica Section C (2008) 64, 9 o505-o507
a=6.5779(18)Å b=7.3593(10)Å c=8.425(2)Å
α=97.277(12)° β=95.631(15)° γ=111.037(12)°
3,3'-[(1<i>RS</i>,3<i>SR</i>)-2-Oxocyclohexane-1,3-diyl]bis[(3<i>RS</i>,3'<i>SR</i>)-3-hydroxyindolin-2-one] dihydrate
C22H20N2O5,2(H2O)
Acta Crystallographica Section C (2013) 69, 9 1081-1084
a=8.3637(9)Å b=21.493(3)Å c=13.0968(14)Å
α=90.00° β=119.941(13)° γ=90.00°
5,5-dimethyl-3-(5-methyl-1H-pyrazol-3-ylamino)cyclohex-3-en-1-one
C12H17N3O
Acta Crystallographica Section C (2000) 56, 12 1457-1459
a=12.5130(3)Å b=9.4275(3)Å c=10.6441(3)Å
α=90.00° β=90.00° γ=90.00°